Lucida Medical Secures Estimated £7.7m to Advance AI-Powered Prostate Cancer Diagnostics

Lucida Medical Ltd, a Cambridge-based innovator in medical technology, has successfully secured an estimated £7.7m in a recent funding round. The company specialises in developing AI-based software designed to enhance the detection, diagnosis, and management of prostate cancer through the analysis of MRI scans.

Founded on 19 November 2019, Lucida Medical addresses a critical need in healthcare by providing clinicians with advanced tools to improve diagnostic accuracy and streamline clinical workflows for prostate cancer. Their flagship product, Pi™ (Prostate Intelligence), is a CE-marked medical device that leverages artificial intelligence and MRI technology to assist doctors in identifying prostate cancer, the most common cancer among men. The software aims to deliver outstanding clinical data, automation, and seamless workflow integration within healthcare systems.

According to the latest available accounts, Lucida Medical employs 15 individuals, while its LinkedIn profile indicates a broader team of 30 professionals. The company's core expertise lies in medical device development, artificial intelligence, medical imaging, MRI, machine learning, image enhancement, oncology, and cancer diagnosis and screening.

The recent funding round saw an estimated £7.7m allotted on 27 March 2026, with the filing date recorded as 17 April 2026. This capital injection is expected to further fuel the development and deployment of Lucida Medical's innovative solutions, expanding its reach and impact within the medical community.

In a recent corporate development, David Fisher was appointed as a director on 18 March 2026. This appointment reflects the company's ongoing strategic growth and its commitment to strengthening its leadership and operational capabilities as it continues to scale its operations and product offerings.

Lucida Medical operates within the dynamic sector of research and experimental development on biotechnology, with its LinkedIn profile also categorising its industry as Medical Equipment Manufacturing. The company's focus on AI-driven diagnostics places it at the forefront of health technology innovation, contributing to advancements in precision medicine and patient care.